Growing community of inventors

Dalheim, Germany

Cornelia Heinz

Average Co-Inventor Count = 6.00

ph-index = 2

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 16

Cornelia HeinzUgur Sahin (4 patents)Cornelia HeinzOzlem Tureci (4 patents)Cornelia HeinzÖzlem Türeci (52 patents)Cornelia HeinzRita Mitnacht-Kraus (4 patents)Cornelia HeinzStefan Woll (4 patents)Cornelia HeinzStefan Jacobs (4 patents)Cornelia HeinzStefan Wöll (4 patents)Cornelia HeinzCornelia Heinz (4 patents)Ugur SahinUgur Sahin (182 patents)Ozlem TureciOzlem Tureci (53 patents)Özlem TüreciÖzlem Türeci (52 patents)Rita Mitnacht-KrausRita Mitnacht-Kraus (16 patents)Stefan WollStefan Woll (15 patents)Stefan JacobsStefan Jacobs (11 patents)Stefan WöllStefan Wöll (4 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Astellas Pharma Gmbh (3 from 416 patents)

2. Ganymed Pharmaceuticals Ag (1 from 50 patents)

3. Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh (1 from 23 patents)

4. Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh (1 from 15 patents)

5. Tron-translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz (1 from 14 patents)

6. Tron Translationale Onkologie an Der Universitatsm (1 from 3 patents)


4 patents:

1. 11826402 - Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma

2. 10946069 - Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer

3. 10314890 - Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer

4. 9770487 - Combination therapy involving antibodies against Claudin 18.2 for treatment of pancreatic adenocarcinoma

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/7/2025
Loading…